Beth Israel Deaconess Medical Center 330 Brookline Ave; CLS-04C3
Boston, MA 02215
Advanced Degree And Training Info:
Year
Institution
Area or Rank
1994
Kyoto University School of Medicine Kyoto Japan
MD
1994
Kyoto University Hospital Kyoto Japan
Internship
1995
Hyogo Prefectural Amagasaki Hospital Hyogo Japan
Residency
2002
Beth Israel Deaconess Medical Center
Research Fellow
2003
Kyoto University Graduate School of Medicine Kyoto Japan
PhD
2006
Harvard Medical School
Instructor
2007
Beth Israel Deaconess Medical Center
Research Associate
Research Team Listing
No team members listed
Areas of Interest:
Cancer & Hematologic
Major Research Theme:
My focus is basic and translational research in human cancers such as lung cancer and leukemia. Currently, our research concentrates on: 1) studying the mechanisms of resistance caused by EGFR tyrosine kinase inhibitors; 2) studying the bcl-2 family proteins which are responsible for tyrosine kinase inhibitor-induced apoptosis; 3) screening and pharmacogenomic studies of compounds which induce cell differentiation of lung cancer cells. These studies will lead to new insights into mutant EGFR-driven tumorgenesis, as well as the identification of novel target pathways for therapeutic intervention in the future.
Costa DB, Nguyen KS, Cho B, Sequist L, Jackman D, Riely G, Yeap B, Halmos B, Kim Jänne PA, Huberman M, Pao W, Tenen DG, and Kobayashi S. Effects of erlotinib in EGFR mutated non-small cell lung cancers with resistance to gefitinib. Clin Cancer Res. 2008 In Press
Costa DB, Halmos B, Kumar A, Schumer ST, Huberman MS, Boggon TJ, Tenen DG, Kobayashi S. BIM mediates EGFR tyrosine kinase inhibitor-induced apoptosis in lung cancers with oncogenic EGFR mutations. PLoS Med 2007 Oct; 4(10):1669-1679; discussion 1680
Kobayashi S, Shimamura T, Monti S, Steidl U, Hetherington CJ, Lowell AM, Golub T, Meyerson M, Tenen DG, Shapiro GI, Halmos B. Transcriptional profiling identifies Cyclin D1 as a critical downstream effector of mutant EGFR signaling. Cancer Res. 2006 Dec 1; 66(23):11389-98.
Kobayashi S, Ji H, Yuza Y, Meyerson M, Wong KK, Tenen DG, Halmos B. An alternative inhibitor overcomes resistance caused by a mutation of the epidermal growth factor receptor. Cancer Res. 2005; 65(16):7096-101.
Kobayashi S, Boggon TJ, Dayaram T, Janne PA, Kocher O, Meyerson M, Johnson BE, Eck MJ, Tenen DG, Halmos B. EGFR mutation and resistance of non-small-cell lung cancer to gefitinib. N Engl J Med. 2005; 352(8):786-92.
External Recognition:
2005 Research Fellowship award, Uehara Memorial Foundation, Japan.
2006 AACR-Merck Scholar-in-Training Award, American Association of Cancer research
2007 NIH/NCI K99
